Golimumab is a human monoclonal antibody which is used as an immunosuppressive medication
Trade name Simponi targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule: a TNF inhibitor.
Golimumab reduces C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates effective modulation of inflammatory markers and bone metabolism.
Pregnancy category US: N (Not classified yet)
It binds to both soluble and transmembrane forms of TNFα.
It is used as a treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Aadministered subcutaneous injection or by intravenous injection.
Approved as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
In a large, double-blind randomized controlled trials in patients with rheumatoid arthritis golimumab in combination with methotrexate was more effective than methotrexate alone.
Among children and young adults with newly diagnosed type 1 diabetes results were better for endogenous insulin production and less exogenous insulin use than placebo.